𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Valproate therapy and nonalcoholic fatty liver disease

✍ Scribed by Gerhard J. Luef; Markus Waldmann; Wolfgang Sturm; Anis Naser; Eugen Trinka; Iris Unterberger; Gerhard Bauer; Monika Lechleitner

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
77 KB
Volume
55
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Nonalcoholic fatty liver disease was defined recently as another symptom of insulin resistance. Continuous therapy with valproate can result in increased body weight and insulin resistance, but no data are yet available on a possible relationship between valproate and nonalcoholic fatty liver disease. We here demonstrate in abdominal ultrasound investigations that characteristics of fatty liver disease were present in 61% of valproate‐treated patients as compared with 23% receiving carbamazepine therapy. Ann Neurol 2004

πŸ“œ SIMILAR VOLUMES

Nonalcoholic fatty liver disease and liv
Nonalcoholic fatty liver disease and liver transplantation
✍ Paul Angulo πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 229 KB

Nonalcoholic fatty liver disease affects a substantial proportion of the general population worldwide. This high prevalence of nonalcoholic fatty liver disease has important consequences in the donor selection process for liver transplantation, and in the posttransplant period given the high recurre

Nonalcoholic fatty liver disease after l
Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease
✍ Kanthi Yalamanchili; Sherif Saadeh; GΓΆran B. Klintmalm; Linda W. Jennings; Gary πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 262 KB

Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples

Hepatic iron and nonalcoholic fatty live
Hepatic iron and nonalcoholic fatty liver disease
✍ Zobair M. Younossi; Terry Gramlich; Bruce R. Bacon; Christi A. Matteoni; Navdeep πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views
Iron and fibrosis in nonalcoholic fatty
Iron and fibrosis in nonalcoholic fatty liver disease
✍ Graeme A. Macdonald; Patrick J. Ward; D. Keith George; Lawrie W. Powell πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 29 KB πŸ‘ 2 views
Adipocytokine levels in nonalcoholic fat
Adipocytokine levels in nonalcoholic fatty liver disease
✍ Teoman Dogru; Cemal Nuri Ercin; Serkan Tapan; Murat Kantarcioglu; Muammer Kara; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 61 KB πŸ‘ 2 views

Li et al. have analyzed golgi phosphoprotein 2 (GOLPH2) serum levels in a cohort of patients with liver cirrhosis, healthy controls, and patients with hepatocellular carcinoma (HCC). They found elevated serum levels of GOLPH2 (sGOLPH2) in early HCC cases. From their findings, the authors conclude th